REG - Uniphar PLC - Full Year Trading Update and Notice of Results

UnipharAnnouncement

30/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240130:nRSd2856Ba&default-theme=true

RNS Number : 2856B  Uniphar PLC  30 January 2024

 

 

Uniphar plc

 

Full Year Trading Update and Notice of Results

 

Dublin, London | 30 January 2024: Uniphar plc (the "Group" or "Uniphar"), an
international diversified healthcare services business addressing the needs of
more than 200 multinational pharmaceutical and medical technology
manufacturers, today announces the following unaudited trading update for the
year ended 31 December 2023.

 

The business performed in line with the Group's expectations for 2023 at both
a gross profit and EBITDA level, while delivering normalised free cashflow
conversion in-line with our medium-term guidance. The Group achieved organic
gross profit growth in excess of 5%.

 

The Group continues to maintain a strong liquidity position, with lower than
projected net debt at year-end.

 

Outlook

Uniphar is well positioned to deliver organic gross profit growth across all
divisions and, consistent with the Group's new medium-term targets, is
targeting organic gross profit growth in 2024 as follows:

 

·      Uniphar Pharma: Double digit

·      Uniphar Medtech: High single digit

·      Uniphar Supply Chain & Retail: Low single digit

 

M&A will continue to play an important role in Uniphar's growth strategy,
and the Group continues to have a disciplined approach to capital allocation
while managing an active pipeline of acquisition opportunities to further
enhance the Group's growth potential.

 

Ger Rabbette, Uniphar Group Chief Executive Officer said:

 

"Today's trading update reflects a strong performance by the Group in 2023.
Following early delivery on our IPO targets, we have created a new divisional
structure to capitalise on our attractive growth opportunities and are now
focused on reaching our ambitious new target of €200m EBITDA over the
medium-term."

 

Notice of Results

 

The Group expects to publish its final results for the year ended 31 December
2023 at 07:00 am (GMT) on 27(th) February 2024.

 

A conference call for analysts and investors will be held at 9.00 am (GMT) on
27(th) February 2024 to discuss the Group's final results. Analysts and
investors who wish to participate should visit www.uniphar.ie
(http://www.uniphar.ie)  to register.

The Company's final results press release and presentation will also be
available on the website at 07.00 am (GMT) on 27(th) February 2024
at www.uniphar.ie (http://www.uniphar.ie) .

 

 

--- ENDS ---

 

 

 

Contact details

 Uniphar Group                                            Tel: +353 (0) 1 428 7777

 Allan Smylie, Head of Strategy and IR

 Davy (Joint Corporate Broker, Nominated Advisor and      Tel: +353 (0) 1 679 6363

 Euronext Growth Listing Sponsor)

 Daragh O'Reilly

 Niall Gilchrist

 Ivan Murphy

 RBC Capital Markets (Joint Corporate Broker)             Tel: +44 (0) 20 7653 4000

 Jamil Miah

 Rupert Walford

 Stifel Nicolaus Europe Limited (Joint Corporate Broker)  Tel: +44 (0) 20 7710 7600

 Matt Blawat

 Ben Maddison

 Francis North

 Q4 PR                                                    Tel: +353 (0) 1 475 1444

 Iarla Mongey, Public Relations Advisor to Uniphar Group

 

 

 

About Uniphar plc

Headquartered in Dublin, Ireland, the Uniphar Group is an international
diversified healthcare services business servicing the requirements of more
than 200 multinational pharmaceutical and medical technology manufacturers
across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply
Chain & Retail. The Group is active in Europe, North America, APAC and
MENA and delivers to 160+ countries.

 

The Company's vision is to improve patient access to pharmaco-medical products
and treatments by enhancing connectivity between manufacturers and healthcare
stakeholders. Uniphar represents a strong combination of scale, growth, and
profitability.

 

Uniphar Supply Chain & Retail

Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in
Ireland with a growing symbol group offering of retail pharmacies. The Group's
strategy for Uniphar Supply Chain & Retail is to grow our wholesale market
share, our symbol group network and our own brand, in-licenced and consumer
products portfolio.

 

Uniphar Medtech

Uniphar Medtech is a leading Pan-European medical device distributor and
solutions partner. The Group's strategy for Uniphar Medtech is to grow our
service offering across Europe and expand our addressable market by serving
new specialities and new manufacturers.

 

Uniphar Pharma

Uniphar Pharma operates a global business with high value services across the
lifecycle of a pharmaceutical product. We enable pharma and biotech companies
to bring innovative medicines to global markets and provide healthcare
professionals with access to medicines they can't source through traditional
channels. Our strategy is to build a leading platform to provide the
specialist support and expertise needed to improve access to these medicines.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFZGZMLLZGDZM